Drugs / O&D-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07369895 | Oct 2025 → Mar 2028 expected | refractory plasma cell neoplasm | O&D BioTech Group CO., Limited | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | O&D-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07369895 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor T Cell (O&D-001) Injection Targeting BCMA and GPRC5D” NCT07369895 ↗ |
| Route | Intravenous | “Single dose administration of O&D-001 via intravenous infusion.” NCT07369895 ↗ |
| Target | GPRC5D | “Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D” NCT07369895 ↗ |